500 patients join biobank to unlock secrets of rare brain vessel diseases
NCT ID NCT07264972
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects blood and urine samples from 500 people with rare brain vessel diseases, such as CADASIL and moya-moya. Researchers aim to find biomarkers that could improve care or identify new treatment targets. Participants are already part of an existing rare disease cohort, and samples will be stored for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify new biomarkers to improve diagnosis and treatment for rare brain vessel diseases.
- What could go wrong
- This is an observational biobank study, not a treatment trial. It may not directly lead to new therapies, and results may take years to impact patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBROVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lariboisière hospital
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a stomach acid blocker shield stroke patients from bleeding?
- New sealant aims to stop brain fluid leaks during neurosurgery
- Zapping the brain to rewire stroke-damaged hands?
- Wrist or groin? major study seeks best route for brain scans
- Brain scans could unlock secrets of childhood disorders
- Stroke rehab progress may predict home vs. facility discharge